Vaxart Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VXRT Nasdaq 8731 https://vaxart.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vaxart Inc

Q1 2024 Vaxart Inc Earnings Call - May 14th, 2024 5:07 pm
Vaxart Inc (VXRT) Q1 2024 Earnings Call Transcript Highlights: Promising Developments and ... - May 14th, 2024 7:07 am
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results - May 13th, 2024 8:01 pm
Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13 - May 7th, 2024 12:00 pm
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers - Apr 30th, 2024 12:00 pm
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024? - Apr 9th, 2024 8:30 pm
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3 - Mar 27th, 2024 12:00 pm
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 20th, 2024 12:00 pm
Estimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT) - Mar 17th, 2024 2:41 pm
Vaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call Transcript - Mar 15th, 2024 5:45 pm
Q4 2023 Vaxart Inc Earnings Call - Mar 15th, 2024 11:33 am
Vaxart Inc (VXRT) Reports Full Year 2023 Financial Results - Mar 14th, 2024 9:35 pm
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results - Mar 14th, 2024 8:01 pm
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14 - Mar 7th, 2024 1:00 pm
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director - Mar 6th, 2024 1:00 pm
VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy? - Feb 26th, 2024 5:00 pm
VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy? - Feb 20th, 2024 2:55 pm
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge - Feb 5th, 2024 1:00 pm
Strong week for Vaxart (NASDAQ:VXRT) shareholders doesn't alleviate pain of three-year loss - Feb 1st, 2024 11:42 am
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate - Jan 19th, 2024 1:30 pm